Innoform Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 09-07-2024
- Paid Up Capital ₹ 0.10 M
as on 09-07-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
- Revenue %
(FY 2021)
- Profit -56.01%
(FY 2021)
- Ebitda -52.64%
(FY 2021)
- Net Worth -164.48%
(FY 2021)
- Total Assets 15.50%
(FY 2021)
About Innoform Lifesciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajeshwara Bomma, Anil Bazaru, Padma Arvapalli, and Four other members serve as directors at the Company.
- CIN/LLPIN
U73200TG2019PTC131093
- Company No.
131093
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Mar 2019
- Date of AGM
16 Sep 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Innoform Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeshwara Bomma  | Managing Director | 25-Nov-2021 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Satya Bomma | Additional Director | 25-Nov-2021 | Current |
| Anil Bazaru | Director | 05-Mar-2019 | Current |
| Padma Arvapalli | Additional Director | 25-Nov-2021 | Current |
| Madhavi Vudaru | Additional Director | 25-Nov-2021 | Current |
| Saritha Appana | Additional Director | 25-Nov-2021 | Current |
| Sridhar Vudaru | Additional Director | 25-Nov-2021 | Current |
Financial Performance of Innoform Lifesciences.
Innoform Lifesciences Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 56.01% decrease in profit. The company's net worth observed a substantial decline by a decrease of 164.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Innoform Lifesciences?
In 2021, Innoform Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Innoform Lifesciences?
Innoform Lifesciences has a workforce of 0 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Innoform Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Innoform Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
